Some of the names on the move ahead of the open.» Read More
Alcoa (AA) kicks off earnings season Wednesday after the bell. Which stocks and sectors look the best?
Slowdown talk hurts tech, commodities, defense stocks today. UBS downgrades IBM on concerns about a slowing in tech orders; Deutsche Bank downgrades Boeing and Goodrich. Commodities weak across the board—metals, steel, iron ore (2nd day in a row.) Defensive stocks—consumer, drugs all strong. Lilly upgraded at Morgan Stanley.
Stocks rebounded to close mixed amid worries over the economy and geopolitical tensions.
Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.
You’ve probably noticed one of the many scenic TV commercials that advertise prescription drugs. But did you notice what some of them are attempting to sell you?
Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.
Merry Christmas! The ECB's decision to inject half a trillion (trillion!) into the global marketplace (technically, they are providing what is essentially unlimited loans at a fixed fate for the next couple weeks) is definitely giving equities a shot in the arm this morning. This should put some pressure on bonds, lower LIBOR rates, and maybe prop up the dollar a bit.
Eli Lilly Tuesday said Sidney Taurel, the drugmaker's long-time chief executive officer, will retire on March 31 and will be succeeded by Chief Operating Officer John Lechleiter.
Earlier this week I blogged about Amgen's negative test results for its anemia drug Aranesp in breast cancer. The studies showed the drug may have caused tumors to grow and death. This morning it almost seems like there's a delayed market reaction.
The drug industry could face plunging sales as patents on some blockbusters are set to expire, according to Thursday’s WSJ. Can you trade the Journal’s grim prognosis?
Eli Lilly Thursday forecast 2008 earnings above Wall Street expectations and said it remained on track to seek U.S. approval this month for prasugrel, a blood clot preventer, which posted mixed results in a recent large clinical trial.
Regular blog readers are well aware of my relentless pursuit of big CEO interviews. So, I wanted to give the backstory to a surprising CEO cancellation of a previously scheduled and confirmed interview today by Bristol-Myers Squibb. A few weeks ago, my producer Ruth and I got tentative confirmation from a Bristol spokesman that the relatively new CEO Jim Cornelius would finally do his first TV interview since taking over the company last year.
I don't know how they all got clustered together--maybe so many of the major pharmaceutical companies meet with Wall Street in early December so everyone can then take off on long vacations--but my hands are full with three big pharma events in as many days. Yesterday, Merck put out guidance.
With little earnings news, analyst conferences appear to be dictating the market. What's the trade heading into next week?
Pfizer (PFE) hit a 52-week low while Merck (MRK) sprinted to a 4 year high, both ahead of analyst meetings. What’s the trade as drug makers get a physical from Wall Street?
Regarding my post from yesterday about Lilly CEO Sidney Taurel, a spokesman left me a voicemail this morning to say it has no intention of backing out of the interview next week. I've got a tentative commitment from Bristol-Myers Squibb to interview its new CEO Jim Cornelius for the first time at that company's analyst meeting next week.
If you arrive for work at CNBC headquarters early enough you can pick up a copy of "The Wall Street Journal" at the lobby desk when you walk in. Today, I grabbed mine and set it down on my desk while I logged onto my computer and cleaned out my inbox.
So, does this mean I'm gonna get scooped by Reuters on Merck stories? I'm just kidding, but that was one of my reactions when I saw the press release this morning from Merck announcing that it's putting the CEO of Reuters, Tom Glocer, on its Board of Directors. The head of a financial data and news company on the Board of a major drug company. Very interesting.
Big drug companies might not be so defensive anymore. Here’s why.
It didn't take long for Japan's Takeda Pharmaceuticals, which trades on the Tokyo exchange, to try to capitalize on the new safety warning for GlaxoSmithKline's diabetes drug Avandia. Last week the FDA slapped a so-called "Black Box"--the agency's most severe warning--on the Avandia label advising patients and doctors about the potential heart attack and stroke risk that's been the subject of so much controversy over the past several months.